By the time Michigan's health officials noticed the first cluster of cyclospora infections in late June, the parasite was already moving faster than the state could track it. Cases climbed from a few dozen in a typical year to more than five thousand within weeks, spread across five states and linked, eventually, to a shredded lettuce supply chain that nobody could pin down with confidence. What is striking about the outbreak is not the pathogen itself but the conditions that allowed it to outrun the response. An entire regional laboratory gone. A state infectious disease bureau short by twenty-three staff. Local health departments stripped of more than a hundred workers. The federal Centres for Disease Control and Prevention, once the backstop for exactly this kind of event, has lost around a third of its own workforce and much of its senior leadership. Communication that used to flow from Washington to the states has slowed to something closer to a trickle.

None of this is really about lettuce. It is about what happens when the unglamorous scaffolding of public health, laboratory capacity, disease surveillance, environmental health staff, is treated as discretionary spending rather than infrastructure. Cuts to that scaffolding rarely produce an immediate, visible failure. They produce a slow degradation that shows up months or years later, in the form of an outbreak nobody can quite explain or contain quickly enough.

Britain has its own version of this story, though the chapter is still being written. Between 2015 and 2024, the ring-fenced public health grant that funds local authorities' health protection work fell by close to £858 million in real terms, according to Local Government Association analysis, even as demand on those services grew. The UK Health Security Agency, assembled from the wreckage of Public Health England in 2021, has spent much of its short life trying to prove it can do more with a settlement that never quite matched its remit. The government has since moved to correct course, with a three year public health grant settlement from April 2026 promising real terms growth and £460 million of capital funding earmarked for pandemic preparedness and laboratory infrastructure. On paper, the direction has reversed.

What the American case illustrates is that reversing a funding line on a spreadsheet does not automatically reverse the capacity loss underneath it. Laboratories that have closed do not reopen overnight. Environmental health officers who left the profession during a decade of squeezed budgets do not return simply because a new settlement has been announced. Surveillance systems that were quietly downgraded, in the American instance, cyclospora itself was made an optional pathogen for national foodborne illness reporting, take years to rebuild to the point where they catch a signal early rather than after hospitalisations have already climbed into the hundreds. The gap between funding restored and capability restored is where outbreaks live.

This matters acutely for Wes Streeting's stated ambition to shift the NHS from treating sickness to preventing it, one of the central pillars of the ten year health plan and the Neighbourhood Health Framework. Prevention sounds like a policy slogan until it requires the unromantic machinery that makes early detection possible: local laboratories that can process a few thousand samples without exceeding budget, environmental health teams who can trace contamination back through a supply chain, and a health security agency with enough staff depth to communicate clearly and quickly when something goes wrong. Michigan's chief medical officer put it plainly when she said that losing one team member on a public health workforce might not be traceable to any single failure, but the effect accumulates until it is unmistakable. Britain has begun putting money back into that workforce. Whether it has begun rebuilding the capability that money is meant to buy is a separate and much harder question, and one that will only be answered the next time something slips through.

The American outbreak offers no comfortable lesson about superior institutions on this side of the Atlantic. It offers a warning about the lag between a funding decision and its consequences, and a reminder that prevention, unlike treatment, only proves its worth in the outbreaks that never happen.